1Werfel T. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy[J].J Dtsch Dermatol Ges, 2009,7:739-742.
2Schneeweiss S, Doherty M, Zhu S,et al. Topical treatments with pimecrolimus, tacrolimus and medium-to high-potency corticos- teroids, and risk of lymphoma[J].Dermatology, 2009,219:7-2 l.
3Huhsch T, Kapp A, Spergel J. irnmunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis [J]. Dermatology, 2005, 211 : 174-187.
5Iraji F, Asilian A, Siadat AH, et al.Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double- blind, placebo-controlled clinical trial[J].J Drugs Dermatol, 2010,9: 684-686.
6Kose O, Arca E, Kurumlu Z, et al.Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo [J].J Dermatolog Treat, 2010, 21:133-139.
7Esfandiarpour I, Ekhlasi A, Farajzadeh S, et al.The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial[J]. J Dermatolog Treat, 2009, 20:14-18.
8Cicek D, Kandi B, Bakar S, et al. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study[J]. J Dermatolog Treat, 2009,20:344-349.
9Ozden MG, Tekin NS, Ilter N, et al.Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study [J].Am J Clin Dermatol, 2010,11:51-54.
10Yan AC, Honig PJ, Ming ME,et al. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory studv[J]. Arch Dermatol,2010,146:57-62.
